Venus Remedies is locked in upper circuit of 10% at Rs 161 after the company said Venus Medicine Research Centre (VMRC), it’s R&D Centre, Venus Medicine Research Centre (VMRC) has been accredited for Good Laboratory Practices (GLP) and norms on Organization for Economic Co-operation and Development (OECD) Principles by National GLP and Compliance Monitoring Authority (NGCMA).
With this, VMRC has become one of the top 25 testing labs of lndia to have received GLP approval, Venus Remedies said in a statement.
This GLP accreditation follows the grant of full membership to India as an OECD member country. Thus, any research and development related data generated in VMRC will be acceptable by the registration authorities of all the OECD member countries such as USA, Japan, Europe and so on, it added.
The stock opened at Rs 154 and hit a low of Rs 149 in early morning deals on BSE. A combined 82,884 shares changed hands on the counter and there are pending buy orders for 31,825 shares on BSE and NSE at 1451 hours.
With this, VMRC has become one of the top 25 testing labs of lndia to have received GLP approval, Venus Remedies said in a statement.
This GLP accreditation follows the grant of full membership to India as an OECD member country. Thus, any research and development related data generated in VMRC will be acceptable by the registration authorities of all the OECD member countries such as USA, Japan, Europe and so on, it added.
The stock opened at Rs 154 and hit a low of Rs 149 in early morning deals on BSE. A combined 82,884 shares changed hands on the counter and there are pending buy orders for 31,825 shares on BSE and NSE at 1451 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%